APPENDIX: CLAIMS NOW PENDING IN THIS APPLICATION

32. (Amended) A method for determining the presence or absence of a breast cancer cell in a patient, the method comprising:

(i) detecting a nucleic acid encoding an amino acid sequence at least 90% identical to SEQ ID NO:2 in a sample from the patient, and

(ii) comparing expression levels of the nucleic acid in the sample from the patient to expression levels of the nucleic acid in a normal tissue sample,

wherein an increase in expression of the nucleic acid in the sample from the patient indicates the presence of a breast cancer cell in the patient.

33. (Amended) The method of claim 32, wherein the sample from the patient comprises isolated nucleic acids.

34. The method of claim 33, wherein the nucleic acids are mRNA.

35. (Amended) The method of claim 32, wherein the sample from the patient is breast tissue.

36. The method of claim 32, wherein the nucleic acid comprises SEQ ID NO:1.

37. The method of claim 32, wherein said detecting step is carried out by using a labeled nucleic acid probe.

38. (Amended) The method of claim 32, wherein said detecting step is carried out by utilizing a biochip comprising a sequence at least 90% identical to SEQ ID NO:1.

39. (New) The method of claim 32, wherein the nucleic acid is at least 95% identical to SEQ ID NO:1.